{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:29:06Z","timestamp":1790713746580,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1016\/j.ymgme.2006.04.013","type":"journal-article","created":{"date-parts":[[2006,6,11]],"date-time":"2006-06-11T13:58:40Z","timestamp":1150034320000},"page":"239-244","source":"Crossref","is-referenced-by-count":49,"title":["Plasma chitotriosidase in male Fabry patients: A marker for monitoring lipid-laden macrophages and their correction by enzyme replacement therapy"],"prefix":"10.1016","volume":"89","author":[{"given":"A.C.","family":"Vedder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cox-Brinkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.E.M.","family":"Hollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.E.","family":"Linthorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.E.M.","family":"Groener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.T.J.","family":"Helmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Scheij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.F.G.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2006.04.013_bib1","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry\u2019s disease. Ceramidetrihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2006.04.013_bib2","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1126\/science.167.3922.1268","article-title":"Fabry\u2019s disease: \u03b1-galactosidase deficiency","volume":"167","author":"Kint","year":"1970","journal-title":"Science"},{"key":"10.1016\/j.ymgme.2006.04.013_bib3","first-page":"3733","article-title":"\u03b1-galactosidase A deficiency: fabry disease","volume":"vol. 3","author":"Desnick","year":"2001"},{"key":"10.1016\/j.ymgme.2006.04.013_bib4","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2006.04.013_bib5","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency\u2014macrophage-targeted glucocerebrosidase for Gaucher\u2019s disease","volume":"324","author":"Barton","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2006.04.013_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human \u03b1-galactosidase A replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2006.04.013_bib7","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ymgme.2006.04.013_bib8","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2362.2004.01424.x","article-title":"Fabry disease: overall effects of agalsidase \u03b1 treatment","volume":"34","author":"Beck","year":"2004","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2006.04.013_bib9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2006.04.013_bib10","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","article-title":"Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease, a prospective strain rate imaging study","volume":"108","author":"Weidemann","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ymgme.2006.04.013_bib11","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/01.md.0000178976.62537.6b","article-title":"The relationship of vascular glycolipid storage to clinical manifestations of fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women","volume":"84","author":"Gupta","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ymgme.2006.04.013_bib12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: influence of \u03b1-galactosidase A activity and genetic mutations on clinical course","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ymgme.2006.04.013_bib13","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2006.04.013_bib14","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/BF02436762","article-title":"Elevated plasma chitotriosidase activity in various lysosomal storage disorders","volume":"18","author":"Guo","year":"1995","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2006.04.013_bib15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10545-005-4416-9","article-title":"Plasma chitotriosidase and CCL18: early biochemical surrogate markers in type B Niemann\u2013Pick disease","volume":"28","author":"Brinkman","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2006.04.013_bib16","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1023\/B:BOLI.0000043025.17721.fc","article-title":"The expanding spectrum of disorders with elevated plasma chitotriosidase activity: an update","volume":"27","author":"Michelakakis","year":"2004","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2006.04.013_bib17","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1399-0004.2004.00219.x","article-title":"The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy","volume":"65","author":"Whybra","year":"2004","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2006.04.013_bib18","doi-asserted-by":"crossref","first-page":"40911","DOI":"10.1074\/jbc.M301804200","article-title":"Transglycosidase activity of chitotriosidase: improved enzymatic assay for the human macrophage chitinase","volume":"278","author":"Aguilera","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2006.04.013_bib19","doi-asserted-by":"crossref","first-page":"25680","DOI":"10.1074\/jbc.273.40.25680","article-title":"The human chitotriosidase gene. Nature of inherited enzyme deficiency","volume":"273","author":"Boot","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2006.04.013_bib20","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0950-3536(97)80034-0","article-title":"Plasma and metabolic abnormalities in Gaucher\u2019s disease","volume":"10","author":"Aerts","year":"1997","journal-title":"Baillieres Clin. Haematol."},{"key":"10.1016\/j.ymgme.2006.04.013_bib21","first-page":"977","article-title":"Chitotriosidase genotype and plasma activity in patients type 1 Gaucher\u2019s disease and their relatives (carriers and non carriers)","volume":"86","author":"Giraldo","year":"2001","journal-title":"Haematologica"},{"key":"10.1016\/j.ymgme.2006.04.013_bib22","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase \u03b1 and \u03b2","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.ymgme.2006.04.013_bib23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1086\/345309","article-title":"Recombinant enzyme therapy for Fabry disease. Absence of editing of human \u03b1-galactosidase A mRNA","volume":"72","author":"Blom","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2006.04.013_bib24","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood.V33.2.379.379","article-title":"Gaucher cells in chronic myelocytic leukemia: an acquired abnormality","volume":"33","author":"Kattlove","year":"1969","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2006.04.013_bib25","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/hep.1840020214","article-title":"Ultrastructural and biochemical liver analyses in Fabry\u2019s disease","volume":"2","author":"Meuwissen","year":"1982","journal-title":"Hepatology"},{"key":"10.1016\/j.ymgme.2006.04.013_bib26","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1161\/01.ATV.19.3.687","article-title":"Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages","volume":"19","author":"Boot","year":"1999","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ymgme.2006.04.013_bib27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10545-005-4415-x","article-title":"Monitoring enzyme replacement therapy in Fabry disease-role of urine globotriaosylceramide","volume":"28","author":"Whitfield","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2006.04.013_bib28","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase \u03b1 for Fabry disease: safety and effects on renal function in a home infusion setting","volume":"21","author":"Schiffmann","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"issue":"Suppl. 91","key":"10.1016\/j.ymgme.2006.04.013_bib29","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1651-2227.2002.tb03120.x","article-title":"X-chromosome inactivation and human genetic disease","author":"Lyon","year":"2002","journal-title":"Acta. Paediatr."},{"issue":"Suppl. 2","key":"10.1016\/j.ymgme.2006.04.013_bib30","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1023\/A:1012492429191","article-title":"Clinically relevant therapeutic endpoints in type I Gaucher disease","volume":"24","author":"Hollak","year":"2001","journal-title":"J. Inherit. Metab. Dis."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719206001703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719206001703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T11:49:02Z","timestamp":1586951342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719206001703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["S1096719206001703"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2006.04.013","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}